Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
76.86
-0.14 (-0.18%)
4:00:02 PM EDT: $76.84 -0.02 (-0.03%)
Mergers / Acquisitions

Bristol Myers Squibb To Acquire HBM Portfolio Company Turning Point Therapeutics For USD 4.1 Bln In Cash

Published: 06/03/2022 15:52 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb to Acquire Hbm Portfolio Company Turning Point Therapeutics for USD 4.1 Billion in Cash.
Today Announces That Its Portfolio Company Turning Point Therapeutics (nasdaq: Tptx) Will Be Acquired by Bristol Myers Squibb (nyse: Bmy) in an All-cash Transaction That Values Company at USD 4.1 Billion.
Acquisition Price of USD 76.
-- per Share Represents a Premium of Approximately 122 Percent to Closing Share Price on 2 June 2022.
Transaction is Expected to Close During Q3 2022.